- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
- Interventions
- WAL0921, Placebo
- Drug
- Lead sponsor
- Walden Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 811
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypogammaglobulinemia, Congenital Heart Disease
- Interventions
- IVIG, Placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Influenza
- Interventions
- Peramivir, Oseltamivir
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 0 Days to 17 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 9
- States / cities
- Shreveport, Louisiana • Dayton, Ohio • Smithfield, Pennsylvania + 6 more
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Efprezimod alfa, Placebo
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
- Conditions
- Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
- Interventions
- pamidronate, saline
- Drug · Other
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Critical Illness, Enteral Nutrition, Enteral Feeding Intolerance
- Interventions
- TAK-954, Metoclopramide, Normal Saline
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 14
- States / cities
- Augusta, Georgia • Idaho Falls, Idaho • Peoria, Illinois + 11 more
- Conditions
- Dehydration
- Interventions
- iv fluid infusion
- Other
- Lead sponsor
- University of Arkansas, Fayetteville
- Other
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- There is no Focus on Any Specific Condition
- Interventions
- Peripheral intravenous catheter placement, Blood draw, Peripheral intravenous catheter, To keep open (TKO) infusion of 0.9% normal saline
- Procedure · Other · Device + 1 more
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Fentanyl Overdose, Fentanyl Poisoning
- Interventions
- Naloxone Hydrochloride, Fentanyl, Sterile Saline, CS-1103
- Drug
- Lead sponsor
- Clear Scientific, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 27
- States / cities
- Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more
- Conditions
- Healthy Volunteer Safety Study
- Interventions
- AB103, Placebo
- Drug
- Lead sponsor
- Atox Bio Ltd
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 21
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more
- Conditions
- Post-Traumatic Stress Disorders, Major Depressive Disorder
- Interventions
- Ketamine, Normal Saline
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pruritus Caused by Drug
- Interventions
- Ondansetron 8mg
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
- Conditions
- Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
- Interventions
- Zoledronic Acid 5Mg/Bag 100Ml Inj, Placebo
- Drug · Other
- Lead sponsor
- California Pacific Medical Center Research Institute
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 2,721 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 77
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 58 more
- Conditions
- Autoimmune Epilepsy
- Interventions
- Intravenous Immunoglobulin, Placebos, Normal Saline
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Alcoholism
- Interventions
- Acamprosate, Yohimbine, mCPP, Saline
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Subarachnoid Hemorrhage
- Interventions
- Sodium nitrite, Saline
- Drug
- Lead sponsor
- Hope Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Appetite Regulation, Obesity
- Interventions
- Exendin-(9-39) Acetate, Saline 0.9%
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 29 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Severe Acute Respiratory Syndrome
- Interventions
- Otilimab, Placebo 1, Placebo 2, Standard of care
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
- Conditions
- Post-ligation Cardiac Syndrome
- Interventions
- Milrinone infusion, Placebo infusion
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 3 Months
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Orange, California • Palo Alto, California + 16 more
- Conditions
- Asthma
- Interventions
- INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 6
- States / cities
- Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Interventions
- Dexmedetomidine, Midazolam and Fentanyl
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 2
- States / cities
- Tucson, Arizona